1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Transgene Biotek Limited

Transgene Biotek Limited

TRABI.BO
Transgene Biotek LimitedIN flagBombay Stock Exchange
3.09
INR
-0.12
- -
234.13MMarket Cap
Transgene Biotek Limited
TRABI.BO
(Bombay Stock Exchange)

Recent

price

3.09

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
2.44
3.99
2.29
0.13
0.04
0.02
0.01
- -
0.01
- -
0.02
0.01
0.01
0.03
0.03
- -
0.03
Revenue per Share
0.03
1.76
-0.31
-17.61
-2.53
-2.84
-2.62
-0.85
-1.16
-1.45
-1.38
-1.37
-0.79
-0.09
-0.09
- -
-0.22
Basic EPS, GAAP
-0.42
3.65
-12.18
-0.28
0.47
0.85
- -
-0.08
-0.23
0.02
- -
0.01
- -
- -
0.16
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
10
12.43
12.12
-5.77
-8.3
-8.76
-11.67
-12.52
-13.68
-15.13
-16.5
-19.46
-20.26
-20.34
-20.61
- -
10.07
Book Value per Share
28.42
32.12
19.86
4.11
4.37
0.66
-0.12
0.29
0.4
0.24
0.14
0.79
0.63
0.55
0.46
- -
0.24
Tangible Book Value per Share
41
66
66
76
76
76
76
76
76
76
76
76
76
76
75
- -
75
Basic Weighted Avg Shares
100
263
150
10
3
2
1
- -
1
- -
2
1
1
2
3
2
2
Sales/Revenue/Turnover
-87.54
67.59
-11.81
-1,859.32
-5,968.78
-11,916.81
-25,393.95
- -
-14,477.56
- -
-5,994.44
-11,734.14
-9,769.69
-219.54
-466.63
-351.61
-351.4
Operating Margin (%)
4
4
10
172
172
205
175
99
99
99
99
99
50
1
1
2
2
Depreciation Expense
1
116
-20
-1,334
-191
-215
-199
-64
-88
-110
-104
-104
-60
-7
-7
-17
-17
Net Income, GAAP
18.54
32.55
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
1.37
44.17
-13.54
-13,597.71
-6,079.27
-11,864.37
-28,699.24
- -
-12,334.25
- -
-6,154.34
-11,998.4
-10,904.9
-279.05
-259.34
-782.62
-782.25
Profit Margin (%)
262
-171
-143
-53
-70
-79
-110
-130
-119
-130
-135
-85
-94
-100
-115
-122
-122
Working Capital
74
64
59
59
63
48
52
38
41
43
45
48
50
51
61
68
68
LT Debt
2,155
3,109
3,219
2,060
1,914
1,744
589
524
436
327
222
174
114
107
100
84
84
Total Equity
-4.02
4.32
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
1.82
15.96
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
0.48
18.93
-2.52
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-2.18
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
101
- -
103
LT Borrowings
64
- -
68
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
76
- -
76
Market Capitalization
315
239
149

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
10
- -
10
Cash, Cash Equivalents & STI
1
- -
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
129
- -
133
Payables & Accruals
- -
- -
- -
ST Debt
101
- -
103
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-23.61%
-17.01%
-16.48%
Free Cash Flow
2,564.6%
5,714.62%
-100.94%
Net Income, GAAP
-0.3%
3.2%
144.48%
Sales/Revenue/Turnover
- -
46.6%
-18.99%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
- -
- -
- -
2
2025
- -
1
1
1
3
2026
- -
1
1
1
2

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.02
-0.02
- -
-0.09
2025
0.03
-0.01
-0.01
-0.09
-0.09
2026
-0.06
-0.05
-0.05
-0.06
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Allakos Inc. (ALLK)
Sagimet Biosciences Inc. (SGMT)
PharmaTher Holdings Ltd. (PHRM.CN)
Senomyx, Inc. (SNMX)
Replimune Group, Inc. (REPL)
Sunmax Biotechnology Co., Ltd. (4728.TWO)
Business
Transgene Biotek Limited is an Indian biotechnology company engaged in the research, development, manufacture, and commercialization of various biopharmaceutical products and medical reagents. Founded in 1990 and headquartered in Hyderabad, India, the company operates primarily in the pharmaceuticals and biotech sectors focusing on oncology, auto-immunity, drug delivery, and biogenerics. Its main product offerings include oral formulations of proteins and peptides utilizing proprietary TrabiORAL technology; biogeneric molecules for disease diagnosis; immuno-diagnostic reagents; pharmaceutical capsules including branded products like Trabidha Plus 200 Capsule; and other chemical and immuno-diagnostic reagents for qualitative and quantitative biochemical estimations. Transgene Biotek's products are marketed in multiple countries including Africa, Russia, China, Malaysia, and the Philippines. In recent years, the company has initiated manufacturing operations at its own facilities with a capacity expansion plan targeting bulk drug production primarily for the Asia-Pacific and Latin American markets, while exploring regulatory approvals and partnerships to enter the European and U.S. markets. The company is actively pursuing strategic alliances and has engaged in technology transfer agreements for monetizing several of its developed products. It has also been involved in discussions about acquisitions to enhance its product portfolio and geographic reach, with a focus on commercialization of novel therapies. Recent major changes include the commencement of manufacturing at a new 4 kiloliter capacity facility along with plans for an additional 64 kiloliter API manufacturing unit, ongoing clinical trials advancing its drug candidates, and active efforts to expand into regulated international markets through partnerships and collaborations. Transgene Biotek remains focused on innovation in oral and nasal drug delivery systems, bringing new formulations to market with significant potential to improve patient outcomes in areas of unmet medical need. The company is listed on the Bombay Stock Exchange under the ticker TRABI and continues to evolve its pipeline and operational capabilities in the biotechnology industry.